선퇴 추출물의 Sprague-Dawley rat를 이용한 단회 경구 투여 독성시험

전병석^{1#}, 정희영^{2#}, 이수은³, 서윤수³, 김중선², 남현화^{3*}, 이지혜^{4*}

1 : 농림축산검역본부 독성평가연구실, 2 : 전남대학교 수의과대학, BK21 Plus Project Team 3 : 한국한의학연구원 한약자원연구센터, 4 : 부산대학교 한의학전문대학원

Single Dose Oral Toxicity Study of Cicadidae Periostracum Extracts in Sprague–Dawley Rats

Byung-Suk Jeon^{1#}, Huiyeong Jeong^{2#}, Sueun Lee³, Yun-Soo Seo³ Joong-Sun Kim², Hyeon Hwa Nam^{3*}, Ji Hye Lee^{4*}

1: Toxicological Evaluation Laboratory, Animal and Plant Quarantine Agency, Gimcheon 39660, Korea, Republic of 2: College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University, Gwangju 61186, Korea, Republic of 3: Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, Naju 58245, Korea, Republic of

4: School of Korean Medicine, Pusan National University, Yangsan 50612, Korea, Republic of

ABSTRACT

Objective : Cicadae Periostracum (CP), which is the discarded shell of the *Cryptotympana atrata* (Fabricius, 1775), is a recognized component of oriental medicine for treatment sore throat, itching, shock, sedation, edema. However, the safety and toxicity of CP have not yet been established. It has been reported that symptoms of addiction or side effects may occur in patients who take high doses of CP or who are hypersensitive to it. Therefore, we investigated the acute toxicity of an CP extracts in Sprague–Dawley (SD) rats.

Methods: To study acute toxicity, five SD rats of each sex per group were treated with CP extracts at single doses of 0, 500, 1000, or 2000 mg/kg administrated by oral gavage, and body weight, clinical signs, and mortality were observed after dosing. At the end of 14-day observation period, all animals were sacrificed and complete hematological and macroscopic examinations were performed.

Results : There were no dead animal and test article-related effects on body weight change or the gross finding. No toxicologically significant results were observed between control and treated groups in hematology. Although salivation related to stress at the highest dose was observed in clinical signs immediately after administration, it is considered to have no toxicological significance.

Conclusion: As the results, we did not find any adverse effect at the dose levels of 500, 1000, or 2000 mg/kg in rats. The minimal lethal dose was considered to be over 2000 mg/kg body weight in rats.

Key words: Traditional Medicine, Cicadae Periostracum, Acute toxicity, Oral administration, SD Rats

· Tel: +82–54–912–0573 · E-mail: bsjeon79@korea.kr

• Tel: +82-62-530-2815 • E-mail: hyyy0e2@gmail.com

These authors contributed equally to this work. • Received : 24 April 2024 • Revis

^{*}Corresponding authors : Ji Hye Lee, School of Korean Medicine, Pusan National University, Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan 46241, Republic of Korea.

[•] Tel: +82-51-510-8459 Hyeon Hwa Nam, Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, 111, Geonjae-ro, Naju-si,

^{58245,} South Korea.

[·] Tel: +82-61-338-7147 · E-mail: namhh@kiom.re.kr

[#]First authors : Byung-suk Jeon, Toxicological Evaluation Laboratory, Animal and Plant Quarantine Agency, 177, Gimcheon, 39660, Republic of Korea.

Huiyeong Jeong : College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwanju, 61186, Republic of Korea

I. Introduction

Utilizing diverse natural resources such as plants. animals, and mineral components is a widespread tradition in traditional medicine. Medicines made from animals and derivatives from their organs have been used in various culture since ancient times $^{1-3)}$. Not only plant materials are commonly utilized in traditional medicine, but also animal products are also widely employed ^{4,5)}. Therapeutic utilization of animals and their products has been a common practice in ancient cultures worldwide. It remains prevalent in many modern societies ^{2,4)}. In India, traditional medicinal practices involve the use of at least 109 animal species. In Northeast Brazil, around 250 animal species are utilized medicinally⁶⁾. Similarly, in Africa, certain studies have reported that various animals are believed to possess healing properties for different diseases ¹⁾. Over 1,500 animal species have been recognized for their therapeutic properties in China⁷⁾.

Cicadae Periostracum (CP), which is the discarded shell of the Cryptotympana atrata (Fabricius, 1775), is a recognized component of traditional Chinese medicine known for its functions such as "dispelling wind and heat," "clearing vision and reducing cloudiness," and "relieving convulsions by dispelling wind"^{8,9)}. CP has a history of being employed to alleviate symptoms like sore throat, hoarseness, itching, and spasms in China^{10,11)}. CP is commonly referred to as "Cicadas" or "Sun-Tae" in Korea. Its origins trace back to an ancient Korean medical text, the Dongui Bogam, classified within the Chung-bu category ¹²⁾. In Korean traditional medicine, CP has been utilized for treating conditions such as epilepsy, shock, smallpox, sedation, edema, and symptoms of night terror ¹²⁾. CP has been reported to have various pharmacological effects, such as dermatitis symptoms-alleviating, anticonvulsant, neuronal apoptosisprotecting, and antioxidant effect ¹³⁻¹⁷.

However, it has been reported that symptoms of addiction or side effects may occur in patients who take high doses of CP or who are hypersensitive to it ¹⁸. This study conducted a single-dose toxicity test using CP, observing mortality rates, clinical symptoms, changes in body weight, hematological examinations, and necropsy results. In this study, we attempted to present scientific evidence on the toxicity effects of CP.

II. Materials and Methods

1. Test substances

CP was purchased from Kwong-Mung-dang Company (Ulsan, Korea) and authenticated by Dr. Goya Choi (Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, Naju, Korea). A voucher specimen (3–18–0038) was deposited at the Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine. Briefly, CP was extracted in distilled water for 3 h under reflux (100 ± 2°C). The extract was filtered, evaporated on a rotary vacuum evaporator, and lyophilized (yield, 6.30%). The powder was kept at 4°C until use. ¹⁴.

2. Animals

Seven-week-old male and female SD (Sprague-Dawley) rats were purchased from Orientbio (Seongnam, Korea) and used acclimatization for 6 days. During acclimatization and experimental periods, animals were kept under free access to food pellets (Teklad Certified Irradiated Global 18 % Protein Rodent Diet, Envigo, USA) and tap water. Animals were housed at 22 \pm 2°C, relative humidity of 55 \pm 10% in a 12 hr light/12 hr dark cycle. This study was approved by the Institutional Animal Care and Use Committee (IACUC) of Korea Conformity Laboratories (Incheon, Korea) based on Animal Protection Act of Republic of Korea (Approval No.: IA20-02696)

3. Experimental Group

Animals (20 males and 20 females) were allocated to four experimental group of CP extract receiving 0, 500, 1000 or 2000 mg/kg.

4. Treatment

After starvation for 4 hr, animals were orally administered with CP extract dissolved in water at doses of 500, 1000, or 2000 mg/kg or its vehicle alone. The application volume (10 mg/kg) was calculated according to the body weight on the treatment day. The oral route is the clinically intended route for the test article.

5. Clinical signs and mortality

Gross appearances of animals were observed immediately and after 30 min, 1, 2, 3, 4, 5, and 6 hr of the administration. Thereafter, they were observed once a day for 14 days. Rats were observed once daily for morbidity and mortality for 14 days. Clinical signs such as posture, gait, fur, skin, eye/pupil, mucus, respiration, response to handling, convulsions, stereotypy and bizarre movements were observed.

6. Body Weight

Individual body weights of animals were measured shortly before test article administration and on 1, 3, 7, and 14 day after treatment thereafter.

7. Macroscopic examination

On day 14 after treatment, all surviving rats were weighted and then sacrificed by cutting the abdominal aorta with posterior vena cava under isoflurane anesthesia for macroscopic observation. These animals were subjected to gross necropsies such as inspection of the outer body surface, cranial, abdominal and thoracic cavity and their contents.

8. Hematological analysis

On the 14th day, animals were weighed, anaesthetized, and euthanized for collection of blood samples. Blood samples were examined for hematology analysis. Hematological parameters were determined using ADVIA 2120i hematology analyzer (Siemens Ireland, Dublin, Ireland). Hematological analysis included measurement of White Blood Cell (WBC) count,

Table 1. Mortalities and clinical signs of rats

differential WBC count, red blood cell (RBC) count, hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), platelet (PLT).

9. Statistical analyses

Weight changes and hematological results of the control group and experimental groups were analyzed for significance by one-way analysis of variance (ANOVA) using SPSS software (SPSS Inc., Chicago, IL, USA). P-value $\langle 0.05$ was considered to be significant. Results are expressed as mean \pm standard deviation (SD).

Ⅲ. Results

1. Mortality and Clinical findings

Mortality and abnormalities in gross appearance of the animals were not observed during the experimental period. During clinical observation, fur, skin, eyes, mucous, membrane, gait, posture and respiration appeared normal. Lacrimation, clonic or tonic movement, piloerection, diarrhea, stereotype and bizarre behaviors were not observed. Salivation was transiently observed at 30 minutes post treatment (Table 1).

a	-		GROU	P(mg/kg)				
SI	EX:MALE —	G1(0)	G2(500)	G3(1,000)	G4(2,000)			
	No. of dead animals	0 / 5 #	0 / 5	0 / 5	0 / 5			
MORTALITIES	%	0	0	0	0			
	No abnormalities detected	5 / 5	5 / 5	5 / 5	4 / 5			
CLINICAL SIGNS	Salivation	0 / 5	0 / 5	0 / 5	1 / 5			
07		GROUP(mg/kg)						
SE	X:FEMALE —	G1(0)	G2(500)	G3(1,000)	G4(2,000)			
	No. of dead animals	0 / 5	0 / 5	0 / 5	0 / 5			
MORTALITIES	%	0	0	0	0			
	No abnormalities detected	5 / 5	5 / 5	5 / 5	5 / 5			
CLINICAL SIGNS	Salivation	0/5	0 / 5	0 / 5	1 / 5			

: Number of animals with the signs / Number of animals examined

2. Body weights

Body weight gain of males and females in experimental groups (CP 500, 1000, and 2000 mg/kg groups) were similar to those of corresponding control groups, showing no significant $(p \ge 0.05)$ differences (Fig. 1).




Fig. 1. Change on Body weights

(A) Male or (B) female rats were fed with CP extract (500, 1000, or 2000 mg/kg) and body weight changes were monitored for 14 days. Data represent the mean \pm S.D.

3. Macroscopic examination

No abnormal findings were observed in macroscopic observation on day 14 (Table 2).

Table 2. Gross findings of rats

SEX : MALE				SEX: FE	X:FEMALE				
opquira		SIGN	5		opaura	SIGNS			
ORGANS -	G1(0)	G2(500)	G3(1,000)	G4(2,000)	ORGANS	G1(0)	G2(500)	G3(1,000)	G4(2,000)
All organs	No gross finding detected	5 / 5 #	5 / 5	5 / 5	All organs	No gross finding detected	5 / 5	5 / 5	5 / 5

#: Number of animals with the signs / Number of animals examined

4. Hematological analysis

Hematological values are reported in Table 3 and 4. Relative levels of neutrophils and monocytes were significantly increased in female rats treated with 2000 mg/kg. However, there was no significant hematological change in male rats treated with CP extracts at any concentration compared with vehicle-treated controls.

Table 3. Hematological	values	of	male	rats
------------------------	--------	----	------	------

Table 3. Hematological values of male rats										
	GROUP(mg/kg)									
TEST ITEM	G1(0)	G2(500)	G3(1,000)	G4(2,000)						
$WBC^1(K/\mu L)$	10.75 ± 1.78 (5)	12.03 ± 1.51 (5)	9.07 ± 1.89 (5)	11.56 ± 1.80 (5)						
$NE^2(K/\mu L)$	1.42 ± 0.30 (5)	1.24 ± 0.43 (5)	1.23 ± 0.33 (5)	1.68 ± 0.42 (5)						
$EO^{3}(K/\mu L)$	0.10 ± 0.02 (5)	0.09 ± 0.03 (5)	$0.06^{*} \pm 0.01$ (5)	$0.05^{*} \pm 0.03$ (5)						
$BA^4(K/\mu L)$	0.00 ± 0.01 (5)	0.01 ± 0.01 (5)	0.01 ± 0.01 (5)	0.00 ± 0.01 (5)						
$LY^{5}(K/\mu L)$	8.86 ± 1.55 (5)	10.22 ± 1.43 (5)	7.45 ± 1.68 (5)	9.46 ± 1.38 (5)						
$MO^{6}(K/\mu L)$	0.25 ± 0.06 (5)	0.35 ± 0.12 (5)	0.25 ± 0.08 (5)	0.27 ± 0.10 (5)						
$LUC^{7}(K/\mu L)$	0.13 ± 0.06 (5)	0.12 ± 0.02 (5)	0.07 ± 0.03 (5)	0.09 ± 0.03 (5)						
NEP ⁸ (%)	13.2 ± 1.8 (5)	10.3 ± 3.3 (5)	13.7 ± 3.1 (5)	14.4 ± 2.1 (5)						

	GROUP(ng/kg)								
TEST ITEM	G1(0)	G2(500)	G3(1,000)	G4(2,000)					
EOP ⁹ (%)	0.9 ± 0.3 (5)	0.7 ± 0.2 (5)	0.7 ± 0.1 (5)	$0.4^* \pm 0.2$ (5)					
BAP ¹⁰ (%)	0.1 ± 0.1 (5)	0.1 ± 0.1 (5)	0.1 ± 0.1 (5)	0.1 ± 0.1 (5)					
LYP ¹¹ (%)	82.3 ± 2.5 (5)	84.9 ± 4.1 (5)	81.9 ± 4.1 (5)	82.0 ± 2.8 (5)					
MOP ¹²⁽⁽ %)	2.4 ± 0.6 (5)	2.9 ± 0.7 (5)	2.9 ± 1.1 (5)	2.3 ± 0.8 (5)					
LUP ¹³ (%)	1.2 ± 0.6 (5)	1.1 ± 0.3 (5)	0.8 ± 0.4 (5)	0.8 ± 0.2 (5)					
$RBC^{14}(M/\mu L)$	7.39 ± 0.27 (5)	7.03 ± 0.30 (5)	7.17 ± 0.21 (5)	7.03 ± 0.26 (5)					
$\mathrm{Hb}^{15}(\mathrm{g/d}\ell)$	14.1 ± 0.3 (5)	13.9 ± 0.6 (5)	14.1 ± 0.6 (5)	13.6 ± 0.3 (5)					
$RDW^{16}(\%)$	11.7 ± 0.4 (5)	11.9 ± 0.3 (5)	11.6 ± 0.4 (5)	12.0 ± 0.1 (5)					
HCT ¹⁷ (%)	44.0 ± 1.0 (5)	43.2 ± 1.8 (5)	43.6 ± 1.5 (5)	42.5 ± 0.9 (5)					
MCV ¹⁸ (fL)	59.5 ± 1.4 (5)	61.4 ± 0.6 (5)	60.8 ± 1.6 (5)	60.4 ± 1.0 (5)					
MCH ¹⁹ (pg)	19.2 ± 0.4 (5)	19.8 ± 0.2 (5)	19.6 ± 0.5 (5)	19.4 ± 0.3 (5)					
$\mathrm{MCHC}^{20}(\mathrm{g/d}\ell)$	32.2 ± 0.3 (5)	32.3 ± 0.3 (5)	32.2 ± 0.4 (5)	32.1 ± 0.3 (5)					
$PLT^{21}(K/\mu L)$	1188 ± 82 (5)	1074 ± 168 (5)	$902^* \pm 95$ (5)	1084 ± 93 (5)					
MPV ²² (fL)	6.1 ± 0.2 (5)	$5.8^{**} \pm 0.1$ (5)	$5.5^{**} \pm 0.1$ (5)	$5.7^{**} \pm 0.2$ (5)					

Data represent the mean \pm S,D (Number of animals), 1: White blood cell, 2: Neutrophil, 3: Eosinophil, 4: Basophil, 5: Lymphocyte, 6: Monocyte, 7: Large unstained cell, 8: Percent of neutrophil, 9: Percent of eosinophil, 10: Percent of basophil, 11: Percent of lymphocyte, 12: Percent of monocyte, 13: Percent of large unstained cell, 14: Red blood cell, 15: Hemoglobin, 16: Red cell distribution width, 17: Hematocrit, 18: Mean corpuscular volume, 19: Mean corpuscular hemoglobin, 20: Mean corpuscular hemoglobin concentration, 21: Platelet, 22: Mean platelet volume. *: Significant difference compared with the control group values, p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared with the control group values, <math>p(0,05, **: Significant difference compared values, p(0,05, **: Significant difference compared values, sign

TEST ITEM	GROUP(mg/kg)									
	G1(0)	G2(500)	G3(1,000)	G4(2,000)						
$WBC^{1}(K/\mu L)$	8.93 ± 1.88 (5)	9.47 ± 2.11 (5)	9.42 ± 1.27 (5)	6.82 ± 1.84 (5)						
$NE^2(K/\mu L)$	0.82 ± 0.26 (5)	0.78 ± 0.36 (5)	1.01 ± 0.34 (5)	1.13 ± 0.69 (5)						
$EO^{3}(K/\mu L)$	0.09 ± 0.01 (5)	0.08 ± 0.01 (5)	0.11 ± 0.05 (5)	0.09 ± 0.02 (5)						
$BA^4(K/\mu L)$	0.00 ± 0.01 (5)	0.01 ± 0.00 (5)	0.00 ± 0.00 (5)	0.00 ± 0.00 (5)						
$LY^{5}(K/\mu L)$	7.79 ± 1.80 (5)	8.27 ± 1.70 (5)	8.05 ± 1.56 (5)	$5.29^{*} \pm 1.39$ (5)						
$MO^{6}(K/\mu L)$	0.17 ± 0.04 (5)	0.23 ± 0.08 (5)	0.18 ± 0.06 (5)	0.23 ± 0.08 (5)						
$LUC^7(K/\mu L)$	0.07 ± 0.04 (5)	0.11 ± 0.02 (5)	0.07 ± 0.03 (5)	0.07 ± 0.03 (5)						
NEP ⁸ (%)	9.3 ± 2.9 (5)	8.0 ± 2.1 (5)	11.2 ± 4.9 (5)	$16.3^* \pm 6.7$ (5)						
EOP ⁹ (%)	1.0 ± 0.3 (5)	0.9 ± 0.1 (5)	1.2 ± 0.4 (5)	1.5 ± 0.4 (5)						
BAP ¹⁰ (%)	0.1 ± 0.1 (5)	0.1 ± 0.1 (5)	0.0 ± 0.1 (5)	0.0 ± 0.1 (5)						
LYP ¹¹ (%)	86.9 ± 2.9 (5)	87.5 ± 2.1 (5)	84.9 ± 5.4 (5)	$77.7^* \pm 5.9$ (5)						
MOP ¹²⁽⁽ %)	1.9 ± 0.4 (5)	2.3 ± 0.4 (5)	1.9 ± 0.7 (5)	$3.3^{**} \pm 0.6$ (5)						
LUP ¹³ (%)	0.8 ± 0.3 (5)	1.3 ± 0.4 (5)	0.7 ± 0.3 (5)	1.1 ± 0.4 (5)						
$\mathrm{RBC}^{14}(\mathrm{M}/\mu\mathrm{L})$	7.29 ± 0.25 (5)	7.18 ± 0.22 (5)	7.01 ± 0.37 (5)	7.04 ± 0.27 (5)						
$\mathrm{Hb}^{15}(\mathrm{g/d}\ell)$	13.5 ± 0.5 (5)	13.9 ± 0.3 (5)	13.4 ± 0.6 (5)	13.3 ± 0.5 (5)						
RDW ¹⁶ (%)	10.8 ± 0.5 (5)	10.9 ± 0.7 (5)	10.8 ± 0.4 (5)	11.0 ± 0.6 (5)						
HCT ¹⁷ (%)	40.6 ± 1.6 (5)	41.4 ± 0.9 (5)	40.0 ± 1.9 (5)	40.3 ± 1.5 (5)						
MCV ¹⁸ (fL)	55.6 ± 0.5 (5)	$57.7^* \pm 1.0$ (5)	57.2 ± 1.1 (5)	57.2 ± 2.9 (5)						

Table 4. Hematological values of female rats

TEST ITEM					GROUI	P(mg/kg)				
	G1(0)			G2(500)			G3(1,000))	G4(2,00	0)
MCH ¹⁹ (pg)	18.5 ± 0.2	(5)	19.3^{**}	-	(5)		± 0.7	(5)	19.0 ± 0.9	(5)
$\mathrm{MCHC}^{20}(\mathrm{g/dl})$	33.3 ± 0.2	(5)	33.5	± 0.3	(5)	33.4	± 0.9	(5)	33.1 ± 0.4	(5)
$PLT^{21}(K/\mu L)$	1005 ± 143	(5)	975	± 61	(5)	1081	± 91	(5)	1057 ± 78	(5)
MPV ²² (fL)	5.8 ± 0.4	(5)	5.9	± 0.2	(5)	6.6^{**}	± 0.3	(5)	$6.8^{**} \pm 0.3$	(5)

Data represent the mean \pm S.D (Number of animals). 1: White blood cell, 2: Neutrophil, 3: Eosinophil, 4: Basophil, 5: Lymphocyte, 6: Monocyte, 7: Large unstained cell, 8: Percent of neutrophil, 9: Percent of eosinophil, 10: Percent of basophil, 11: Percent of lymphocyte, 12: Percent of monocyte, 13: Percent of large unstained cell, 14: Red blood cell, 15: Hemoglobin, 16: Red cell distribution width, 17: Hematocrit, 18: Mean corpuscular volume, 19: Mean corpuscular hemoglobin, 20: Mean corpuscular hemoglobin concentration, 21: Platelet, 22: Mean platelet volume. *: Significant difference compared with the control group values, p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared with the control group values, Significant difference compared with the control group values, <math>p(0.05, **: Significant difference compared values, Significant difference compared values, Significant difference compared value

IV. Discussion

CP is an herbal medicine widely used in oriental medicine to relieve rashes and itching, improve vision, relieve spasms, and soothe the throat. However, it has been reported that CP can cause toxicity and side effects in patients who take too much of it or have a hypersensitive constitution. Thus, it is considered necessary to look into its toxicity ¹⁸. CP has been reported to decrease activity in mice and rabbits. When administered at 1.12 g/kg for 7 days, it can cause changes in kidney-related serum biochemistry in rabbits ¹⁸.

The test article CP extracts at a dose of 0, 500, 1000, or 2000 mg/kg was orally administrated to male and female SD rats to evaluate its acute toxicity. Clinical signs, mortality, body weight changes, and macroscopic examination were observed for 14 days following a single treatment. No significant changes were observed in this study. However, salivation in clinical signs was observed in a male rat treated with the highest doses of CP extracts. Salivation in rats has been reported to be dose-related ¹⁹⁾. Test substances that are quite unpleasant or have immediate side effects may cause stress during administration. Clinical signs such as salivation may indicate that the animal is experiencing stress ²⁰⁾. However, it was not accompanied by other pathological changes such as body weight or macroscopic examination. Clinical signs observed transiently after administration were not observed from one hour after treatment. Therefore, it was considered to have no toxicological significance.

In terms of hematology, increase of relative levels of neutrophils and monocytes were observed in female rats after administration of the highest doses of CP extracts. However, these hematological changes were within the normal historical range ^{21,22}. They were detected only in female rats, suggesting that they were not related to test article toxicity.

In this study, we did not find any toxicological significant clinical changes. Body weight changes and macroscopic examinations were not significant compared to the control group. Thus, LD_{50} of CP extracts was considered to be greater than 2000 mg/kg. Overall, results showed no toxicity significance. However, a single oral dose acute toxicity test is not sufficient to determine toxicity to CP extracts. Further investigation should include 4– and 13–week repeated oral dose toxicity studies and genotoxicity studies. This study observed toxicity after a single dose of CP extracts. It could be used as a basis for the safety of CP.

V. Conclusions

In a single oral toxicity study with CP extracts in SD rats, no mortality was observed following administration of the test article. No toxicological changes were observed in clinical findings, body weight changes, hematological analysis, or macroscopic examination attributable to CP extracts. Therefore, the LD_{50} of CP extracts is considered to exceed 2000 mg/kg.

Acknowledgments

This research was supported by grants for a

Development of Sustainable Application for Standard Herbal Resources from the Korea Institute of Oriental Medicine, Republic Korea (KSN2012320) and Regional Innovation Strategy (RIS) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE)(2021RIS-002).

References

- Adeola MO. Importance of wild animals and their parts in the culture, religious festivals, and traditional medicine, of Nigeria. Environmental Conservation. 1992; 19(2):125–134. doi.org/10.1017/ s0376892900030605
- Lev E. Traditional healing with animals (zootherapy): medieval to present-day Levantine practice, J Ethnopharmacol. 2003;85(1):107-118. doi.org/10.1016/ s0378-8741(02)00377-x
- Alves RRN, Barbosa JAA, Santos SLDX, Souto WMS, Barboza RRD. Animal-based remedies as complementary medicines in the semi-arid region of northeastern Brazil. Evid Based Complementary Alternat Med. 2011;179876. doi:10.1093/ecam/nep134
- Msigwa AM, Mulungu LS, Mdangi ME, Kilonzo BS. Knowledge and attitudes of community on small mammalian carnivores in MBOMIPA wildlife management area, south-central Tanzania. Afri J Sci Res 2015;6(4):46-9.
- Magige FJ. Traditional medicinal uses of small mammal products: a case study of the African savannah hares, crested porcupines and rock hyraxes in Serengeti district, Tanzania. Tanz J Sci 2015; 41:64-71
- Alves RRN, Rosa IL. Why the use of animal product in traditional medicines? J Ethnobiol Ethnomed. 2005;1:5. doi.org/10.1186/1746-4269-1-5
- Mahawar MM, Jaroli DP. Traditional zootherapeutic studies in India: a review. J Ethnobiol Ethnomed. 2008;4:17. doi.org/10.1186/1746-4269-4-17
- Yang L, Li GY, Wang JH. The research progress of chemical constituents and pharmacology of Cicadae Periostracum. Journal of Nongken Medicine, 2011; 33(2):184-6.
- Cao XC, Mao Q, Zhou ZR, He Y, Li SL. Research progress on Cicadae Periostracum. Chinese Medicine Journal of Research Practice. 2019;33(5):77-82.
- 10. Hsieh MT, Peng WH, Yeh FT, Tsai HY, Chang YS. Studies on the anticonvulsive, sedative and

hypothermic effects of Periostracum Cicadae extracts. J Ethnopharmacol. 1991;35(1):83-90. doi.org/10. 1016/0378-8741(91)90136-2

- Xu MZ, Lee WS, Han JM, Oh HW, Park DS, Tian GR, Jeong TS, Park HY. Antioxidant and anti– inflammatory activities of N-acetyldopamine dimers from Periostracum Cicadae. Bioorg Med Chem. 2006;14(23):7826-34. doi.org/10.1016/j.bmc.2006. 07.063
- Song BK, Won JH, Kim SC, Historical medical value of Donguibogam. J Pharmacopuncture. 2016;19(1) :16-20. doi.org/10.3831/kpi.2016.19.002
- Kim BNR, Chae JW. Effects of Cicadae Periostracum (CP) in allergic contact dermatitis (ACD) induced by DNCB in Mice. J Pediatr Korean Med. 2015; 29(2):1-15. doi.org/10.7778/jpkm.2015.29.2.001
- 14. Lim HS, Kim JS, Moon BC, Choi GY, Ryu SM, Lee J, Ang MJ, Jeon MJ, Moon CJ, Park GH. Cicadidae Periostracum, the cast-off skin of Cicada, protects dopaminergic neurons in a model of Parkinson's disease, Oxid Med Cell Longev. 2019:5797512. doi.org/10.1155/2019/5797512
- 15. Park GH, Moon BC, Ryu SM, Kim WJ, Lim HS. Cicadidae Periostracum attenuates atopic dermatitis symptoms and pathology via the regulation of NLRP3 inflammasome activation. Oxid Med Cell Longev. 2021:8878153. doi.org/10.1155/2021/887 8153
- 16. Guo MF, Zhang HH, Zhong P, Xu JD, Zhou SS, Long F, Kong M, Mao Q, Li SL. Integrating multi– Type component determination and anti-oxidant/ -inflammatory assay to evaluate the impact of pre– molting washing on the quality and bioactivity of Cicadae Periostracum. Molecules 2022;27(22): 7683. doi.org/10.3390/molecules27227683
- 17. Zhang Q, Li RL, Tao T, Sun JY, Liu J, Zhang T, Peng W, Wu CJ. Antiepileptic effects of Cicadae Periostracum on mice and its antiapoptotic effects in H₂O₂-stimulated PC12 cells via regulation of PI3K/Akt/Nrf2 signaling pathways. Oxid Med Cell Longev. 2021:5598818. doi.org/10.1155/2021/5598818
- Roh SS, Kim SM, Seo BI, A philological study on poisoning and adverse reaction of Cicadae Periostracum, The Journal of Jeahan Oriental Medical Academy. 2011;9(1):13-8.
- Silva AV, Norinder U, Liiv E, Platzack B, Öberg M, Törnqvist E. Associations between clinical signs and pathological findings in toxicity testing. ALTEX. 2021;38(2): 198-214. doi.org/10.14573/altex.2003311
- Everds NE, Snyder PW, Bailey KL, Bolon B, Creasy DM, Foley GL, Rosol TJ, Sellers T. Interpreting stress responses during routine toxicity studies: a

review of the biology, impact, and assessment. Toxicol Pathol. 2013;41(4):560-614. doi.org/10.11 77/ 0192623312466452

- 21. Giknis MLA, Clifford CB. Clinical laboratory parameters for Crl:CD(SD) rats. Charles River Laboratories 2006 [cited 2024 May 7]. https://www. criver.com/sites/default/files/resources/rm_rm_r_c linical_parameters_cd_rat_06.pdf
- 22. Han ZZ, Xu HD, Kim KH, Ahn TH, Bae JS, Lee JY, Gil KH, Lee JY, Woo SJ, Yoo HJ, Lee HK, Kim KH, Park CK, Zhang HS, Song SW. Reference data of the main physiological parameters in control Sprague–Dawley rats from pre–clinical toxicity studies. Lab Anim Res. 2010;26(2); 153–164. doi.org/10.5625/lar.2010.26.2.153